Chronic mirabegron treatment increases human brown fat, HDL cholesterol, and insulin sensitivity
O'Mara A, Johnson J, Linderman J, Brychta R, McGehee S, Fletcher L, Fink Y, Kapuria D, Cassimatis T, Kelsey N, Cero C, Sater Z, Piccinini F, Baskin A, Leitner B, Cai H, Millo C, Dieckmann W, Walter M, Javitt N, Rotman Y, Walter P, Ader M, Bergman R, Herscovitch P, Chen K, Cypess A. Chronic mirabegron treatment increases human brown fat, HDL cholesterol, and insulin sensitivity. Journal Of Clinical Investigation 2020, 130: 2209-2219. PMID: 31961826, PMCID: PMC7190915, DOI: 10.1172/jci131126.Peer-Reviewed Original ResearchConceptsBAT metabolic activityIntravenous glucose tolerance testGlucose tolerance testΒ3-AR agonistInsulin sensitivityTolerance testMetabolic diseasesObesity-related metabolic diseasesWhite adipose tissue lipolysisBrown adipose tissue thermogenesisOpen-label studyTotal bile acidsHuman brown fatHigher insulin sensitivityAdipose tissue lipolysisAdipose tissue thermogenesisPET/CTΒ3-adrenergic receptor agonistIntramural Research ProgramChronic pharmacological stimulationMetabolic activityMirabegron therapyMirabegron treatmentPrimary endpointSecondary endpoints